Myungmoon Pharm Co Ltd
KRX:017180
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
NiCAN Ltd
XTSX:NICN
|
CA |
|
U
|
Umweltbank AG
SWB:UBK
|
DE |
Myungmoon Pharm Co Ltd
Research & Development
Myungmoon Pharm Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Myungmoon Pharm Co Ltd
KRX:017180
|
Research & Development
-₩3.1B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-66%
|
|
|
Yuhan Corp
KRX:000100
|
Research & Development
-₩198.2B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Research & Development
-₩169.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Research & Development
-₩195.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Research & Development
-₩8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Research & Development
-₩5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Myungmoon Pharm Co Ltd
Glance View
MYUNGMOON Pharm Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-07-10. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The firm is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
See Also
What is Myungmoon Pharm Co Ltd's Research & Development?
Research & Development
-3.1B
KRW
Based on the financial report for Sep 30, 2025, Myungmoon Pharm Co Ltd's Research & Development amounts to -3.1B KRW.
What is Myungmoon Pharm Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-66%
Over the last year, the Research & Development growth was -28%. The average annual Research & Development growth rates for Myungmoon Pharm Co Ltd have been -32% over the past three years , -38% over the past five years , and -66% over the past ten years .
